You are viewing a free limited preview of Agios Pharmaceuticals, Inc.
Get Full Access To This Report 
| or | Upgrade to PrivCo Premium |
| $99 Single Company Access | Instant Full Site-Wide Access Currently 50% Off Until May. 31! |
Agios Pharmaceuticals, Inc. is a privately-held, venture capital backed biopharmaceutical company formerly known as Cancer Metabolism Therapeutics, Inc. Agios Pharmaceuticals discovers and develops therapeutics in the field of cancer metabolism. Founded by Dr. Lewis C. Cantley, Dr. Tak Wah Mak, Dr. Craig B. Thompson, and Dr. Shin-San Su, Agios Pharmaceuticals is headquartered in Cambridge, Massachusetts. In 2011. Agios closed a $130 million upfront in a discovery deal with Celgene in 2010, which in 2011 made an additional $20 million payment to Agios to extend its exclusive deal with Agios in the cancer metabolism field from three to four years.
| Company Tags: | VC Backed |
| Formerly Named: | Cancer Metabolism Therapeutics, Inc. |
| Fiscal Year End: | 12/31 |
| City: | Cambridge |
| State/Province: | Massachusetts |
| Country: | United States |
| Phone: | View |
| Website: | www.agios.com |
| Founders: | Lewis Cantley |
| Healthcare > Pharmaceuticals |
| Technology > Biotechnology > Biopharmaceuticals |
The PrivCo Industry Classification System™ (PICS) is our proprietary, modernized industry classification system, geared especially toward privately-held companies and including newer emerging sub-industries that are not reflected in other outdated industry classification systems, such as SIC and NAICS.
$99 Single Company AccessInstant Full Site-Wide Access| Date | Status | Target | Buyer | Deal Type | Price | |
| Details | Apr. 2010 | Completed | View1 | View | Joint Venture / Partnership Formed Minority Stake Purchase | View |
| Details | Oct. 2011 | Completed | View2 | View | Joint Venture / Partnership Formed | View |
| 1 | Celgene gained an exclusive option...Read More → |
| 2 | Follow-on investment...Read More → |
Full-length notes are available with Single Report Access or PrivCo Premium Subscription. |
Missing a deal? Tell us about it! tips@privco.com
$99 Single Company AccessInstant Full Site-Wide Access| Date | Investor | Round | Investor Type | |
| Jul. 2008 | View | A | Venture Capital | |
| Jul. 2008 | View | A | Venture Capital | |
| Jul. 2008 | View | A | Venture Capital | |
| Details | Total Round A View | |||
| Apr. 2010 | View | B | Corporate | |
| Details | Total Round B View | |||
| Nov. 2011 | View | C | Corporate | |
| Nov. 2011 | View | C | Venture Capital | |
| Nov. 2011 | View | C | Venture Capital | |
| Nov. 2011 | View | C | Venture Capital | |
| Nov. 2011 | View | C | Venture Capital | |
| Details | Total Round C1 View | |||
| Total of Funding Shown Above View | ||||
| 1 | Commonwealth Ventures partner...Read More → |
Full-length notes are available with Single Report Access or PrivCo Premium Subscription. |
Missing a deal? Tell us about it! tips@privco.com
$99 Single Company AccessInstant Full Site-Wide AccessBUSINESS OVERVIEW
Agios Pharmaceuticals, Inc. is a drug developer with a focus on cancer metabolism and rare metabolic genetic diseases. Agios has an active research and discovery pipeline with several treatments nearing the clinical trial phase. Agios is currently being backed by several VC firms as well as Celgene Corporation, a publicly-held pharmaceutical company based in New Jersey.
Agios spent the first several months of its existence employing scientific rigor translating a broad idea of cancer metabolism into intellectual property. Agios has already applied for dozens of patents (see exhibits attached to this report). Once the science was secure, the firm turned to searching for partners with deep pockets and a common goal.
CONTRACT WITH CELGENE CORPORATION
In April of 2010, Agios entered into a contract with Celgene Corporation which focuses on Agios' cancer metabolism drugs and their discovery, development, and commercialization. In exchange for a massive amount of… Continue Reading →
$99 Single Company AccessInstant Full Site-Wide Access|
Get Full Access To This Report
| or | Upgrade to PrivCo Premium |
| $99 Single Company Access | Instant Full Site-Wide Access Currently 50% Off Until May. 31! |
PrivCo is the authority for financial & business data on major private companies, including:
| Private Companies | 209,401 |
| Private Investors | 12,095 |
| Private M&A Deals | 43,310 |
| VC/Funding Rounds | 36,248 |
| Total Data Points | 95,786,176 |
You are viewing a free limited preview of Agios Pharmaceuticals, Inc.
PrivCo is the premier source for business and financial data on major, non-publicly traded corporations, including family owned, private equity owned, venture backed, and international unlisted companies. Click here to learn more.
PDF VERSION: Download Company Report in PDF Format
EXPORT COMPANY'S DATA TO EXCEL:
Full Online Report